- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
- Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
- Zai Lab Announces Participation in September Investor Conferences
- Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
More ▼
Key statistics
On Monday, Zai Lab Ltd (1ZL:FRA) closed at 16.80, 35.48% above the 52 week low of 12.40 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.80 |
---|---|
High | 16.80 |
Low | 16.80 |
Bid | 17.90 |
Offer | 18.40 |
Previous close | 16.80 |
Average volume | 450.80 |
---|---|
Shares outstanding | 99.61m |
Free float | 97.44m |
P/E (TTM) | -- |
Market cap | 1.82bn USD |
EPS (TTM) | -3.50 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 08:17 BST.
More ▼